Noninvasive assessment of characteristics of novel anti-HER2
Por um escritor misterioso
Descrição
Multidisciplinary Approach to Novel Therapies in Cardio-Oncology
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
Histological and immunohistochemical analysis for HER2 expression in
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer - eBioMedicine
Anti-HER2 therapy mechanisms of action and resistance. The left part of
Molecules, Free Full-Text
PDF) HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
Frontiers Pre-Clinical Study of the [18F]AlF-Labeled HER2 Affibody for Non-Invasive HER2 Detection in Gastric Cancer
The landscape of d16HER2 splice variant expression across HER2-positive cancers
Frontiers Application of a Novel 68Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients
Clinicopathological characteristics of the study population with
Frontiers Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
Assessment of Novel Mesothelin-Specific Human Antibody Domain VH-Fc Fusion Proteins-Based PET Agents
Summary of bioinformatics analysis that were used for HER2 peptide
de
por adulto (o preço varia de acordo com o tamanho do grupo)
